肺鳞30月，父亲永远地走了

+ O* b" J6 T; A% K' Y2 N
4.15 复查
6 H. e' h3 K. b( V) B医生认为CT才做一个月，结果稳定，这次查个血就够了，我认同，上次就CA125增长比较多，这次开单查了CEA、CA125、CA153、CA199，NSE。去年9月之前没记录，尚未找到规律，再来几次可能就知道哪个敏感了。
如果2992还有效，是否改成吃8停5？目前状态很好，乳铁蛋白有奇效？

4.17 昨天抽了血，今天出报告：
CEA 1.76
' z+ W' D& ^* [+ [+ V/ i- Q. BCA125 162.6 继续升高，估计2992耐药或部分耐药了
CA199 8.48
CA153 17.82
NSE 14.95

CT上个月做稳定，因此这次未做，CA125继续上升，纠结要不要化疗。医生提议目前生活质量很好，以CT为准，暂不管指标上升。
纠结ing

- c2 ?7 M) B. j& y  _7 ]
现在考虑的方案：
% D5 y/ U6 X  I0 \1、试试易(平安老师认为肺癌不试试易可惜）
7 i2 c" r! k  @2 k# p+ `3 z2、2992+半量xl184
7 ^: }2 a' Y# S* C/ Z8 S3、2992加量
凡德有试过，无效

. i( @* k( r* @/ S6 C. E
爱老虎油！ 2013/4/17 星期三 18:56:31
9 @+ D" z# l$ v  i' V0 e3 D! M易用过吗？没用过试试易吧，肺，不用易太可惜了
滴水(luxd)  20:20:13
平安姐，我父亲是鳞、吸烟，是不是也试试
滴水(luxd)  20:34:25
( A# f6 m8 j: q: S/ V8 ~* t之前就是考虑鳞+男性+吸烟，直接上的特。现在考虑：
8 l4 Y4 g0 B% G1、试试易
2、2992+半量xl184
5 M2 ^  i6 h, k$ N: ?: H/ J3、2992加量
( U/ y- |. W# X9 n6 x' h( Q凡德有试过，无效
8 g9 l; u& O7 v6 ]爱老虎油！  21:31:42
% i. x3 N6 a, n" K如果病情紧急就上2，不紧急就试试易
! T2 |$ n+ }: P2 f: L7 G- I

9 J* d: L# a, q, b
( S/ r. w5 [- E$ z考虑方案4：替吉奥
( V) u- J8 Y- k1 I6 g1 z
3 H0 F& S; O) J  a' R2 }, vS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
# D. `5 f( [1 T  C% M% w
- w3 m: k, i. E/ K# ~- }% S替的疾病控制率，腺比非腺高很多：57.9%vs20%

S-1联合铂类，效果与病理类型无关（即鳞和腺相当），这与培美不同，可能是作用TS的方式不同。
- z+ |6 D# S+ g( l0 Yhttp://ar.iiarjournals.org/content/30/7/2985.full.pdf
单药却与病理类型有关？

综合平安老师、老马建议和自己判断，决定采用方案四，口服替吉奥。原因：
1、特、2992均已耐药，易有效的可能性很低；
" i& ]+ z' m. T, c( a7 e1 y) J6 C2、2992趋于耐药，如果没有有效手段，反正都要化疗了，口服替是比较轻松的化疗方案；
( r; {* f" w; C' q2 B3、如果不准备把2992用绝，联用方案也先不考虑：
--2992+184，平安老师认为在危急的时候用；
--2992+替http://www.ncbi.nlm.nih.gov/pubmed/20530710，2992已经耐药，就先不考虑联用了；
% t7 h5 H+ M) c# i% P0 S5、如果替有效，那怕只是稳定，也为切换回特创造条件，如果无效，就去多西他赛化疗。
还有什么要考虑的？每次情况变化，做决定都是犹豫不决。

4.22 开始替吉奥，60mg bid

关注！

论坛里有好几家在用替，关注中。